<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Arrhythmia-induced cardiomyopathy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Arrhythmia-induced cardiomyopathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Arrhythmia-induced cardiomyopathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cynthia M Tracy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J McKenna, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiomyopathies are diseases of the heart muscle, inclusive of a variety of myocardial disorders that manifest with various structural and functional phenotypes and are frequently genetic. Although some have defined cardiomyopathy to include myocardial disease caused by known cardiovascular causes (such as hypertension, ischemic heart disease, or valvular disease), current major society definitions of cardiomyopathy exclude heart disease secondary to such cardiovascular disorders [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a> and  <a class="medical medical_review" href="/z/d/html/3516.html" rel="external">"Causes of dilated cardiomyopathy"</a>.)</p><p>The prognosis in patients with dilated cardiomyopathy is variable and dependent on the cause; importantly, there are some etiologies that may improve or resolve following treatment. One such cause is an arrhythmia-induced cardiomyopathy (also known as tachycardia-induced cardiomyopathy, tachycardia-mediated cardiomyopathy, and tachymyopathy), a relatively rare though well-recognized entity caused by long-standing tachycardia, which in most instances is readily treatable with a good prognosis [<a href="#rid3">3</a>]. Arrhythmia-induced cardiomyopathy has been reported with nearly all types of tachyarrhythmias and frequent ectopy, both supraventricular and ventricular [<a href="#rid4">4</a>].</p><p>A common clinical problem is determining whether the tachycardia is the primary cause of the patient's cardiomyopathy, or if the tachycardia is secondary to a cardiomyopathy of different etiology. This topic will discuss arrhythmia-induced cardiomyopathy as a primary cause of cardiomyopathy. Arrhythmias occurring in the setting of a specific cardiomyopathy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4926.html" rel="external">"Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a> and  <a class="medical medical_review" href="/z/d/html/4931.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Anatomy, histology, and clinical manifestations", section on 'Ventricular arrhythmias'</a>.)</p><p class="headingAnchor" id="H617141798"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>While the exact incidence of arrhythmia-induced cardiomyopathy remains unclear, an association between tachycardia and cardiomyopathy has been recognized for some time [<a href="#rid5">5-8</a>]. Virtually every form of supraventricular tachyarrhythmia, including ectopic atrial tachycardia (AT), nonparoxysmal junctional tachycardia, and atrial fibrillation (AF), has been associated with reversible left ventricular (LV) dysfunction or "cardiomyopathy." The development of a cardiomyopathy has also been documented with ventricular tachyarrhythmias and frequent ectopic beats [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/1041.html" rel="external">"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm"</a> and <a class="local">'Frequent ectopic beats'</a> below.)</p><p>Some insight into the prevalence of arrhythmia-induced cardiomyopathy can be derived from cohort studies of patients undergoing catheter ablation for symptomatic arrhythmias. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Among a cohort of 331 patients who were referred for catheter ablation of incessant AT, myocardial dysfunction was present in 9 percent of patients [<a href="#rid12">12</a>]. Patients with an arrhythmia-induced cardiomyopathy were younger (mean age 39 versus 51 years), more frequently male (60 versus 38 percent), and had incessant or very frequent paroxysmal tachycardia (100 versus 20 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among a cohort of 625 patients undergoing catheter ablation for a variety of tachyarrhythmias, a tachycardia-induced cardiomyopathy was present in 2.7 percent (17 of 625 patients) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among a cohort of 1269 patients undergoing ablation for atrial flutter, 184 had reduced LV ejection fraction (LVEF; &lt;40 percent) at baseline [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Chronic tachycardia ultimately produces significant cardiac structural changes, including LV dilation and cellular morphologic changes [<a href="#rid15">15-19</a>]. However, the exact mechanism by which tachycardia produces these changes is not well defined.</p><p>Animal models, initially developed in the general investigation of heart failure (HF), have been studied extensively in the evaluation of arrhythmia-induced cardiomyopathy. Rapid pacing produces changes in animals that are similar to those observed in humans, including a marked depression of LVEF, elevated filling pressures, depressed cardiac output, and increased systemic vascular resistance [<a href="#rid16">16-18,20-24</a>]. These changes are generally reversible with cessation of the tachycardia, although in some cases LVEF may not return to baseline [<a href="#rid24">24,25</a>]. Similar findings have been reported in an animal model following the delivery of premature ventricular complexes/contractions (PVCs; also referred to as premature ventricular beats or premature ventricular depolarizations) in a bigeminal pattern for 12 weeks, which resulted in LV dilation and reduction in LVEF [<a href="#rid26">26</a>].</p><p>The morphologic and biochemical changes that result from an arrhythmia-induced cardiomyopathy also may produce electrophysiologic abnormalities. In a canine model, chronic tachycardia was associated with ventricular arrhythmias (including polymorphic ventricular tachycardia [VT] and sudden death) that result from a prolongation in repolarization [<a href="#rid27">27</a>].</p><p>Many alterations in neurohumoral and cellular activation have been described, and several factors probably contribute to the development of rate-related myocardial dysfunction. Although data supporting certain potential mechanisms are compelling, it remains unclear whether they play an etiologic role or if they arise as a consequence of tachycardia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Depletion of myocardial energy stores and myocardial ischemia</strong> – Studies in animal models have shown that persistent tachycardia depletes high-energy stores as evidenced by reduced myocardial levels of creatine, phosphocreatine, and adenosine triphosphate (ATP), and diminished activity of the Na-K-ATPase pump [<a href="#rid28">28-30</a>]. These changes are probably due to alterations in cellular metabolism with mitochondrial injury and increased activity of Krebs cycle oxidative enzymes [<a href="#rid15">15,20</a>].</p><p></p><p class="bulletIndent1">Myocardial ischemia may play a role in the development of arrhythmia-induced cardiomyopathy. Similar depletions in high-energy stores are seen in ischemic models following vessel occlusion, situations where high-energy stores are rapidly depleted and LV dysfunction occurs [<a href="#rid31">31,32</a>]. High-energy stores return to normal within days after the ischemic insults. Tachycardia-induced depletion of high-energy stores, which may be mediated in part by ischemia, is reversible and may explain the reversibility of this cardiomyopathy.</p><p></p><p class="bulletIndent1">Abnormalities in subendocardial to subepicardial flow ratios and impaired coronary flow have been found in arrhythmia-induced cardiomyopathy [<a href="#rid33">33-36</a>]. The impaired coronary blood flow occurs in association with elevation in cardiac filling pressures and impaired LV diastolic function [<a href="#rid25">25,37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal calcium handling and beta adrenergic</strong> <strong>responsiveness</strong> – Abnormalities in both calcium channel activity and sarcoplasmic reticulum calcium transport may contribute to the myocardial dysfunction in arrhythmia-induced cardiomyopathy [<a href="#rid20">20,35</a>]. Diminished beta-adrenergic responsiveness has also been described and may be due to reduced myocyte beta-1 receptor density (downregulation) [<a href="#rid37">37,39,40</a>]. The reduction in beta receptor density and responsiveness is independent of hemodynamic and neurohumoral factors [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxidative stress and injury</strong> – In patients with AF and atrial dysfunction, there is histologic evidence of oxidative stress and injury in the atrial myocardium [<a href="#rid42">42</a>]. This results in peroxynitrite formation, which modifies myofibrillar proteins, contributes to loss of fibrillar protein function, and alters myofibrillar energetics.</p><p></p><p class="bulletIndent1">Support for the role of oxidative stress comes from one animal study which found that the administration of the antioxidant vitamins E, C, and <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a> attenuated the cardiac dysfunction and prevented beta receptor downregulation produced by rapid cardiac pacing [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic</strong> <strong>basis</strong> <strong>and ACE gene</strong> <strong>polymorphism</strong> – An association has been reported between a gene polymorphism and arrhythmia-induced cardiomyopathy. Levels of angiotensin converting enzyme (ACE) are associated with a 287 base pair insertion (I)/deletion (D) polymorphism in intron 16 of the ACE gene. The DD genotype is associated with increased serum ACE levels and a higher incidence of both ischemic and idiopathic dilated cardiomyopathy. In a study comparing 20 patients with arrhythmia-induced cardiomyopathy, 20 controls with persistent tachycardia but normal LV function, and 24 normal volunteers, the DD genotype was significantly more common in the patients with arrhythmia-induced cardiomyopathy [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathologic and immunologic findings</strong> – Among a cohort of 189 patients with new onset HF and reduced LVEF not related to valvular or ischemic heart disease, 19 patients met criteria for tachycardia-induced cardiomyopathy. Endomyocardial biopsies in the tachycardia-induced cardiomyopathy patients showed a stronger myocardial expression of major histocompatibility complex class II molecule and enhanced infiltration of CD68<sup>+ </sup>macrophages compared with patients with idiopathic dilated cardiomyopathy. Compared to patients with ischemic cardiomyopathy, those with tachycardia induced cardiomyopathy had fewer T cells and macrophages. Fibrosis was also less prominent in the tachycardia induced cardiomyopathy patients. However, electron microscopy in these patients showed abnormal mitochondrial distribution and enhanced myocyte size. RNA expression analysis showed alterations in metabolic pathways [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h1">ARRHYTHMIAS ASSOCIATED WITH ARRHYTHMIA-INDUCED CARDIOMYOPATHY</span><span class="headingEndMark"> — </span>A number of tachyarrhythmias have been associated with arrhythmia-induced cardiomyopathy, including AF, atrial flutter, atrial tachycardia (AT), reentrant supraventricular tachycardias, and VT [<a href="#rid11">11,46-60</a>]. In addition, very frequent ectopic beats, both atrial and ventricular, have been associated with arrhythmia-induced cardiomyopathy. Regardless of the arrhythmia, therapy to restore normal sinus rhythm or to slow the ventricular rate (or eliminate ectopy) appears to result in an improvement in LV function  (<a class="graphic graphic_table graphicRef59233" href="/z/d/graphic/59233.html" rel="external">table 1</a>). However, most descriptive series include only a small number of patients.</p><p class="headingAnchor" id="H617142075"><span class="h2">Supraventricular arrhythmias</span></p><p class="headingAnchor" id="H10"><span class="h3">Atrial fibrillation and atrial flutter</span><span class="headingEndMark"> — </span>Epidemiologic studies have shown that patients with AF are at increased risk for HF [<a href="#rid61">61</a>]. In some patients, restoration of sinus rhythm or control of the rapid ventricular rate markedly improves or even normalizes the LVEF, indicating that the LV dysfunction was primarily due to the rapid AF rather than another etiology. Improvement in LV function is seen with both rhythm and rate control, although it may be more likely with rhythm control. (See  <a class="medical medical_review" href="/z/d/html/1041.html" rel="external">"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm"</a>.)</p><p>There is an association between HF and AF, and it is often not possible to determine which is causative. Nevertheless, an estimated 25 to 50 percent of patients with LV dysfunction and AF have some component of arrhythmia-induced cardiomyopathy [<a href="#rid4">4,62-64</a>].</p><p>There are less data on the frequency and predictors of arrhythmia-induced cardiomyopathy in patients with atrial flutter. In one study of patients undergoing ablation for atrial flutter, 25 percent had evidence for cardiomyopathy prior to ablation [<a href="#rid65">65</a>]. Of these, 57 percent had significant improvement in their LVEF postablation. The only predictor of reversibility of cardiomyopathy in this study was average heart rate. Similarly, in a cohort of 1269 patients undergoing ablation for atrial flutter, 184 had reduced LVEF (&lt;40 percent) at baseline. Of these patients with reduced LVEF, 103 patients (56 percent) had marked improvement in LVEF at six months. Those who experienced improvement in the LVEF had similar survival to patients who did not have baseline depressed LVEF. Those whose LVEF failed to improve had a three-fold higher mortality [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Atrial tachycardia</span><span class="headingEndMark"> — </span>Incessant AT, an infrequent cause of symptomatic supraventricular tachyarrhythmia, can cause myocardial dysfunction in approximately 10 percent of patients [<a href="#rid12">12</a>]. Children are more likely than adults to present with arrhythmia-induced cardiomyopathy due to incessant AT. When AT is seen in adults, it is more commonly associated with another cardiac problem, and distinguishing the effect of tachycardia from that of the underlying cardiac disease may be difficult. (See  <a class="medical medical_review" href="/z/d/html/900.html" rel="external">"Focal atrial tachycardia", section on 'Incessant AT resulting in cardiomyopathy'</a> and  <a class="medical medical_review" href="/z/d/html/14407.html" rel="external">"Atrial tachyarrhythmias in children", section on 'Focal atrial tachycardia'</a>.)</p><p>Incessant AT and ectopic AT have been associated with the development of cardiomyopathy that can be reversed with restoration of sinus rhythm [<a href="#rid46">46-52</a>]. Improved techniques for catheter ablation frequently permit definitive therapy for AT, which can lead to the resolution of myocardial dysfunction with a high degree of success [<a href="#rid12">12,46,52</a>]. (See  <a class="medical medical_review" href="/z/d/html/900.html" rel="external">"Focal atrial tachycardia", section on 'Treatment of incessant AT'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Reentrant supraventricular tachycardias</span><span class="headingEndMark"> — </span>Reentrant supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reciprocating tachycardia (AVRT), are more commonly paroxysmal but can cause a persistent tachycardia. Cases of arrhythmia-induced cardiomyopathy have been described with persistent junctional reciprocating tachycardia, accessory pathway mediated tachycardia (ie, AVRT) and AVNRT [<a href="#rid50">50,54-57</a>]. In the absence of other factors, the cardiomyopathy related to an incessant reentrant supraventricular tachycardia is reversible following catheter ablation [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/976.html" rel="external">"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway"</a> and  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>.)</p><p class="headingAnchor" id="H617142111"><span class="h2">Ventricular arrhythmias</span><span class="headingEndMark"> — </span>Only rare reports have described reversible cardiomyopathy related to VT, since this arrhythmia is usually associated with some form of underlying structural heart disease. However, idiopathic LV tachycardia or right ventricular outflow tract VT can arise in structurally normal hearts [<a href="#rid9">9,10,54</a>]. In rare cases, these arrhythmias are persistent or repetitive enough to result in a cardiomyopathy. In one study of patients with repetitive monomorphic VT and/or premature ventricular complexes/contractions (PVCs), an arrhythmia-induced cardiomyopathy was seen in 9 percent, all of which improved with treatment [<a href="#rid66">66</a>]. Similar to supraventricular arrhythmias, the myopathy usually reverses following ablation of the arrhythmia [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/965.html" rel="external">"Ventricular tachycardia in the absence of apparent structural heart disease"</a>.)</p><p>Unlike monomorphic VT, which can be present and hemodynamically stable for extended periods of time, polymorphic VT, which is generally an unstable rhythm, and ventricular fibrillation, a non-perfusing rhythm, are not associated with arrhythmia-induced cardiomyopathy.</p><p class="headingAnchor" id="H18539470"><span class="h2">Frequent ectopic beats</span></p><p class="headingAnchor" id="H14"><span class="h3">Frequent ventricular ectopy</span><span class="headingEndMark"> — </span>Very frequent ventricular ectopy in the form of PVCs has been associated with a reversible cardiomyopathy, even in the absence of sustained ventricular arrhythmias [<a href="#rid11">11,59,66-74</a>]. While most earlier studies defined "frequent" as greater than 10 percent of overall heartbeats, in contemporary practice a cutoff of &gt;15 percent of all heartbeats is more commonly used. Although some patients with similarly high PVC burdens can maintain normal cardiac function, PVC-induced cardiomyopathy has also been reported in patients with PVC burdens as low as 4 to 5 percent.</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective observational cohort study of 80 patients (59 percent male, mean age 53 years) with frequent PVCs (mean PVC burden 22 percent) and reduced LVEF (≤50 percent) who underwent catheter ablation, 53 patients (66 percent) had successful long-term elimination of PVCs, with significant improvement in LVEF and New York Heart Association (NYHA) functional class [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2014 systematic review and meta-analysis of radiofrequency ablation for the treatment of idiopathic PVCs originating from the right ventricular outflow tract, catheter ablation was associated with a significant improvement in LVEF, though the meta-analysis was limited by significant heterogeneity among the studies [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/122361.html" rel="external">"Premature ventricular complexes: Treatment and prognosis"</a>.)</p><p></p><p>In addition to the overall frequency of PVCs, QRS duration, epicardial site of origin of PVCs, and resulting dyssynchrony all appear to play a role in the development of cardiomyopathy and are associated with outcomes following catheter ablation. Greater dyssynchrony increases the risk of cardiomyopathy, wider QRS complexes appear more likely to result in cardiomyopathy with a lower overall burden of PVCs while also being associated with longer times to normalization of LV systolic function following ablation, and epicardial PVC origin also appears to predict delayed LV function recovery [<a href="#rid74">74,76-80</a>].</p><p class="headingAnchor" id="H18539509"><span class="h3">Frequent atrial ectopy</span><span class="headingEndMark"> — </span>Premature atrial complexes (PACs; also referred to as premature atrial beats, premature supraventricular complexes, or premature supraventricular beats) are usually benign, but a high burden of PACs has been associated with a reversible cardiomyopathy [<a href="#rid81">81,82</a>].</p><p class="headingAnchor" id="H2314329"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of arrhythmia-induced cardiomyopathy is variable but usually involves signs and/or symptoms related to the tachyarrhythmia (eg, palpitations, dyspnea, chest discomfort, etc), HF (eg, dyspnea, edema, weight gain, orthopnea, etc), or both. In our experience, HF symptoms are more common since patients with symptomatic tachyarrhythmias will frequently seek medical attention earlier in the course of their care and prior to the development of a cardiomyopathy. The approach to the patient with suspected arrhythmia-induced cardiomyopathy includes a thorough history and physical examination, with appropriately selected tests to establish the diagnosis and assess acuity, severity, and etiology. Several professional societies have issued recommendations for the evaluation of patients with suspected HF or cardiomyopathy [<a href="#rid83">83-86</a>].</p><p class="headingAnchor" id="H2430195"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>The clinical presentation of arrhythmia-induced cardiomyopathy is variable but usually involves symptoms of palpitations or HF. Patients may present with palpitations or other symptom (eg, dyspnea, chest discomfort) related to the rapidity or irregularity of their arrhythmia. However, those with more rapid heart rates typically present with symptoms related to the inappropriate heart rate before enough time has elapsed to result in a cardiomyopathy. In contrast, patients with tachycardia but a relatively slower heart rate and no obvious symptoms may have little or no awareness of the arrhythmia. While such patients without palpitations are occasionally discovered during a routine medical exam for other reasons, typically they present with fatigue, decreased exercise tolerance, or symptomatic HF.</p><p>Given that patients with more rapid heart rates often present earlier with symptoms related to the tachycardia, some investigators have hypothesized that patients with atrial arrhythmias who subsequently develop arrhythmia-induced cardiomyopathy have slower overall heart rates than patients who do not develop arrhythmia-induced cardiomyopathy. Published reports in both adult and pediatric populations support this hypothesis:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective cohort study of 331 patients who had undergone ablation for atrial tachycardia (AT), among whom 9 percent presented with evidence of arrhythmia-induced cardiomyopathy, those with arrhythmia-induced cardiomyopathy had slower ventricular heart rates during tachycardia compared with patients who did not have arrhythmia-induced cardiomyopathy (120 versus 149 beats per minute) [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/900.html" rel="external">"Focal atrial tachycardia", section on 'Incessant AT resulting in cardiomyopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective cohort study of 16 pediatric patients with focal AT, those with AT arising from the atrial appendages were more likely to be asymptomatic at presentation, more likely to have a ventricular heart rate less than 120 beats per minute, and more commonly presented with arrhythmia-induced cardiomyopathy [<a href="#rid87">87</a>].</p><p></p><p class="headingAnchor" id="H617142203"><span class="h2">ECG findings</span><span class="headingEndMark"> — </span>All patients should have an electrocardiogram (ECG) to document the cardiac rhythm and ventricular heart rate. Whenever possible, obtaining prior ECGs can be extremely helpful to determine whether ambiguous P wave morphologies are related to the sinus node (as seen on prior tracings) versus an ectopic atrial focus. There are no specific ECG findings that distinguish patients with and without arrhythmia-induced cardiomyopathy, and the ECG findings will vary depending upon the underlying tachyarrhythmia. However, by definition, all patients with an arrhythmia-induced cardiomyopathy should have a heart rate greater than 100 beats per minute.</p><p class="headingAnchor" id="H5490489"><span class="h1">APPROACH TO THE DIAGNOSIS</span><span class="headingEndMark"> — </span>Arrhythmia-induced cardiomyopathy is defined by the presence of a sustained tachycardia (or frequent episodes of tachycardia or very frequent ectopy) which results in LV systolic dysfunction. Determining which of the pathologies (the arrhythmia or the cardiomyopathy) is the primary pathologic process is key to establishing the diagnosis. Usually the diagnosis of arrhythmia-induced cardiomyopathy can only be made following a successful trial of therapy to slow the ventricular rate or to restore sinus rhythm along with the exclusion of other potential causes of cardiomyopathy.</p><p>Patients in whom arrhythmia-induced cardiomyopathy is suspected should undergo continuous cardiac monitoring for 24 to 48 hours and have non-invasive imaging to assess cardiac structure and function. For most patients, a transthoracic echocardiogram is the preferred test for assessing cardiac structure and function due to its widespread availability and ease of performance; however, cardiovascular magnetic resonance (CMR) imaging is a reasonable alternative approach in centers with expertise in this modality.</p><p class="headingAnchor" id="H2430238"><span class="h1">DIAGNOSTIC TESTING</span><span class="headingEndMark"> — </span>Once arrhythmia-induced cardiomyopathy is suspected, appropriately selected tests can help to establish the diagnosis. All of the following are performed as part of the initial evaluation.</p><p class="headingAnchor" id="H5490749"><span class="h2">Cardiac monitoring</span><span class="headingEndMark"> — </span>Heart rate over time should be continuously measured for 24 to 48 hours using inpatient telemetry or ambulatory (Holter) monitoring to document the average heart rate and, in some cases, provide additional information on the underlying rhythm [<a href="#rid88">88</a>]. A sustained heart rate greater than 100 beats per minute, and particularly greater than 120 beats per minutes, is consistent with arrhythmia-induced cardiomyopathy. Because of the potential reversible nature of arrhythmia-induced cardiomyopathy, if uncertainty persists regarding the cardiac rhythm, full invasive electrophysiologic studies may be necessary to establish the underlying cardiac rhythm and guide the optimal therapy. (See <a class="local">'Treatment'</a> below and  <a class="medical medical_review" href="/z/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies"</a>.)</p><p class="headingAnchor" id="H5490755"><span class="h2">Assessment of cardiac structure and function</span><span class="headingEndMark"> — </span>All patients with suspected arrhythmia-induced cardiomyopathy should undergo an assessment of cardiac structure and function to document LV size and function, in particular LVEF. Transthoracic echocardiography is the most common and widespread test for documenting cardiac structure and function, but CMR imaging is an alternative approach. While there are no absolute echocardiographic parameters that can distinguish arrhythmia-induced cardiomyopathy from other forms of dilated cardiomyopathy, in general, the LV end-diastolic dimension tends to be smaller in patients with arrhythmia-induced cardiomyopathy [<a href="#rid4">4,89</a>].</p><p>In patients with improved LVEF after treatment of an arrhythmia, CMR may be useful for the evaluation of cardiac structure and function. Patients who have a CMR that demonstrates a low LVEF or late gadolinium enhancement have incomplete resolution of cardiac injury [<a href="#rid90">90</a>]. Alternatively, in assessing the underlying cause of arrhythmia-induced cardiomyopathy, patients in one study with frequent premature ventricular complexes/contractions (PVCs) who failed to improve LVEF after treatment were found to have late gadolinium enhancement on CMR, and likely the cause of the cardiomyopathy was not purely tachycardia mediated [<a href="#rid91">91</a>].</p><p>Studies have suggested the use of two-dimensional strain echocardiography as a tool to predict recovery from arrhythmia induced cardiomyopathy [<a href="#rid92">92</a>]. In a study of 71 patients with presumed tachycardia-induced cardiomyopathy, a lower LVEF at baseline and higher relative apical longitudinal strain ratio (RALSR) were associated with no recovery in LVEF during follow-up. However, by multivariate analysis the RALSR was found to be a significant predictor of functional recovery after the arrhythmia was treated.</p><p class="headingAnchor" id="H5490763"><span class="h2">Excluding other causes of cardiomyopathy</span><span class="headingEndMark"> — </span>Patients with newly diagnosed HF and/or cardiomyopathy require an assessment for genetic and other causes of LV dysfunction and exclusion of significant underlying coronary heart disease (CHD). Decisions on the initial use of stress testing or coronary angiography should be made based on the presence or absence of symptoms suggestive of CHD and the individual patient's likelihood of CHD. The differential diagnosis of dilated cardiomyopathy, and the approach to excluding CHD, are discussed in greater detail separately. While patients with HF and cardiomyopathies of other etiologies may exhibit rapid heart rates (eg, persistent sinus tachycardia), this can usually be distinguished from an arrhythmia-induced cardiomyopathy by comparison of ECG findings over time (eg, sinus P wave morphology) and response to treatment. An important part of the evaluation is a careful review of the family history, and when the phenotype is clear, genetic testing should be recommended. Several of the genetically determined arrhythmogenic cardiomyopathies can present with frequent ectopy (PVCs, nonsustained VT, and/or AF in association with LV dilation and/or impaired function, eg, desmoplakin, filamin C, lamin AC, desmin) [<a href="#rid93">93,94</a>]. (See  <a class="medical medical_review" href="/z/d/html/3516.html" rel="external">"Causes of dilated cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy", section on 'Detection of coronary artery disease'</a>.)</p><p class="headingAnchor" id="H5490376"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The initial treatments for a patient with HF and suspected arrhythmia-induced cardiomyopathy are the same as those used in most other patients with HF with reduced ejection fraction (eg, angiotensin converting enzyme [ACE] inhibitors or angiotensin II receptor blockers [ARBs], beta blockers, diuretics) and tachyarrhythmias (eg, rate-control medications, consideration of antiarrhythmic drugs and/or cardioversion). However, because of the potentially reversible nature of arrhythmia-induced cardiomyopathy, efforts should be made to achieve adequate ventricular heart rate control or to restore sinus rhythm [<a href="#rid4">4</a>]. Additionally, given the potentially reversible nature of this condition, an adequate trial of therapy is required prior to assessment of the need for cardiac resynchronization therapy or an implantable cardioverter-defibrillator. (See  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a> and  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a> and  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Pharmacologic therapy'</a>.)</p><p class="headingAnchor" id="H5490863"><span class="h2">Patients with atrial fibrillation or flutter</span><span class="headingEndMark"> — </span>For patients in whom AF or atrial flutter is the suspected cause of cardiomyopathy, the initial approach to management is similar to other patients with HF and includes prompt rate control with AV nodal blockers and appropriate anticoagulation. (See  <a class="medical medical_review" href="/z/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure"</a>.)</p><p>Beyond these initial steps, controversy still exists as to whether rate control or rhythm control is the optimal therapy for AF- or atrial flutter-induced cardiomyopathy. Our strategy for management is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For minimally symptomatic patients with AF in whom adequate rate control is achieved, we continue medical therapy. In patients with a cardiomyopathy whose origin is suspected to be AF or atrial flutter, heart rate control through either rate control or rhythm control can be effective at improving cardiac function [<a href="#rid95">95-98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with AF who remain significantly symptomatic or in whom adequate rate control is not achieved with medical therapy alone, we pursue a rhythm control strategy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with atrial flutter, rapid ventricular rates, and newly recognized LV systolic function, rate control may be difficult to achieve with medication; in these patients, we perform early electrical cardioversion.</p><p></p><p>Management of AF and/or atrial flutter is geared towards avoidance of thromboembolic events, reduction of symptoms, and avoidance of arrhythmia-induced cardiomyopathy. Control of heart rate can be met through either a rate control strategy with atrioventricular (AV) nodal blocking agents (or ablation and pacer implant in cases of multiple drug failures) or through maintenance of sinus rhythm (rhythm control strategy). Strategies for rate control versus rhythm control are discussed elsewhere, and choices of agents are dictated by cardiac structure, underlying pathology, and function. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1069.html" rel="external">"Restoration of sinus rhythm in atrial flutter", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a>.)</p><p>At initial presentation of the patient with rapid ventricular rates and newly recognized depressed EF, the concern exists that at least some component is related to arrhythmia-induced cardiomyopathy. This is particularly suspected in younger patients with severe symptoms from the AF. A trial of early cardioversion is warranted in these patients with subsequent monitoring for improvement in cardiac function [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H5490869"><span class="h2">Patients with another SVT</span><span class="headingEndMark"> — </span>For supraventricular tachyarrhythmias (SVTs) other than AF or atrial flutter that result in arrhythmia-induced cardiomyopathy, restoration of sinus rhythm is the usual goal. Options for the restoration of sinus rhythm include electrical cardioversion, antiarrhythmic drugs, and catheter ablation of the arrhythmia. The initial choice of modality will vary depending upon the underlying SVT as well as the local expertise and availability of options (ie, some centers do not perform catheter ablation) but should be made in conjunction with an electrophysiologist experienced in the treatment of sustained tachyarrhythmias.</p><p>Certain SVTs are more amenable to electrical cardioversion (eg, atrioventricular nodal reentrant tachycardia), while others are often refractory or recurrent following cardioversion (eg, atrial tachycardia). Often, atrial arrhythmias can be refractory to antiarrhythmics, and AV nodal blocking agents may be required in high doses to achieve appropriate heart rates. In patients with depressed LVEF, it is important to avoid agents that have a higher likelihood of proarrhythmia (eg, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>) or that could further depress LVEF (eg, <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a>). If an ablation is performed, close follow-up is required even after successful ablation because of the tendency for cardiomyopathy to recur if tachycardia recurs. (See  <a class="medical medical_review" href="/z/d/html/900.html" rel="external">"Focal atrial tachycardia", section on 'Catheter ablation'</a> and  <a class="medical medical_review" href="/z/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Catheter ablation'</a> and  <a class="medical medical_review" href="/z/d/html/14407.html" rel="external">"Atrial tachyarrhythmias in children", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia", section on 'Catheter ablation'</a>.)</p><p class="headingAnchor" id="H5490881"><span class="h2">Patients with frequent ectopy</span><span class="headingEndMark"> — </span>For patients presenting with a high burden of premature ventricular complexes/contractions (PVCs) and newly recognized cardiomyopathy, initial management is to look for underlying causes (such as CAD, valvular heart disease, arrhythmogenic right ventricular dysplasia [ARVD], etc) and initiation of guideline-based optimal medical therapy for HF [<a href="#rid100">100</a>]. Correction of electrolytes and initiation of beta blockers are typical first therapies. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p>Given the possibility of arrhythmia-induced cardiomyopathy in patients with a high PVC burden (eg, &gt;15 to 20 percent of total beats on a 24-hour ambulatory monitor) and associated with LV dysfunction, we generally pursue radiofrequency catheter ablation [<a href="#rid100">100-102</a>]. Catheter ablation of high-frequency PVCs has emerged as a safe and effective therapy and may be considered if medical management is ineffective or poorly tolerated and depending on patient preference [<a href="#rid59">59,74,103-105</a>]. While it is not possible to specify an exact percentage (PVC burden) for which a patient might benefit from ablation of frequent PVCs as studies have had a wide range in their inclusion criteria, consideration may be given with a burden of above 10 percent, but our approach is typically to offer ablation at a higher burden (eg, &gt;15 to 20 percent PVCs). The approach to catheter ablation in patients with a high PVC burden is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/122361.html" rel="external">"Premature ventricular complexes: Treatment and prognosis", section on 'Catheter ablation'</a>.)</p><p class="headingAnchor" id="H2139139230"><span class="h2">Patients with refractory tachyarrhythmias</span><span class="headingEndMark"> — </span>In the event that a supraventricular arrhythmia is likely the cause of cardiomyopathy and cannot be primarily ablated, AV node ablation with either biventricular pacing or conduction system pacing is a reasonable approach to management.</p><p>While there are no studies that specifically address the strategy of AV nodal ablation and biventricular pacemaker placement in patients with arrhythmia-induced cardiomyopathy, there is indirect evidence to support this approach. In a trial that included patients with HF, a narrow QRS, and permanent AF but who did not explicitly have arrhythmia-induced cardiomyopathy, patients assigned to medical rate control had a higher risk of death or rehospitalization due to HF or worsening of HF when compared with patients assigned to AV node ablation and cardiac resynchronization therapy (38 versus 10 percent; hazard ratio 0.28, 95% CI 0.11-0.72) [<a href="#rid106">106</a>]. The effect of this approach on recovery of LVEF was not reported.</p><p>Other trials and studies of patients with preexisting AV node block, HF, and various causes of LV systolic dysfunction are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p class="headingAnchor" id="H5491423"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Whereas the initial cardiomyopathy may have taken months to develop, recurrent tachycardia can lead to an abrupt decline in LVEF. Diastolic dysfunction can persist even after systolic function has normalized and can lead to decreased coronary flow reserve. In patients who develop a recurrence of the arrhythmia, the increased myocardial oxygen demand in the face of the decreased reserve can lead to redevelopment of cardiomyopathy [<a href="#rid107">107,108</a>]. As such, close ongoing monitoring with clinic visits, ambulatory (Holter) monitoring, and echocardiography are essential. Although there are minimal data and no society guidelines regarding the frequency of monitoring in these patients, we follow up with patients using a combination of clinic visits, echocardiography, and ambulatory monitoring every three to six months for one to two years following the initial clinical improvement.</p><p>The following is a typical follow-up schedule:</p><p class="bulletIndent1"><span class="glyph">●</span>Four to six weeks after initial presentation – Clinical follow-up, ECG.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three months after initial presentation – Clinical follow-up, ECG, echocardiogram, outpatient ambulatory monitor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Six months after initial presentation – Clinical follow-up, ECG.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Twelve months after initial presentation – Clinical follow-up, ECG, echocardiogram, ECG, outpatient ambulatory monitor if symptoms suggest recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eighteen to 24 months after initial presentation – Clinical follow-up, ECG.</p><p></p><p>If complete recovery of EF is noted and angiotensin converting enzyme (ACE) inhibitors and beta blockers are tapered off, additional monitoring is required to be sure that EF remains normal [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2430284"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Following the restoration of sinus rhythm or ventricular rate control of the presenting tachycardia, most patients will have significant improvement and/or normalization of LVEF over a period of months. As such, patients who have not experienced sudden cardiac arrest or a sustained ventricular arrhythmia, and whose LVEF has improved to 40 percent or greater, usually do not require implantation of an implantable cardioverter-defibrillator (ICD). (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p>In some patients whose LVEF has normalized, the LV chamber may remain somewhat enlarged. Despite the apparent normalization of cardiac function when a tachycardia has been terminated or rate controlled, ultrastructural abnormalities of the myocardium may persist [<a href="#rid60">60</a>]. Additional evidence for persistent myocardial abnormality despite normalization of systolic function was seen in a study of successfully ablated patients with atrial tachycardia. These patients demonstrated LV structure and function changes including diffuse fibrosis on contrast-enhanced CMR imaging long after successful ablation (64±36 months)<strong> </strong>[<a href="#rid90">90</a>]. As noted previously, late-gadolinium enhancement on CMR suggests the presence of fibrosis and identifies irreversible structural changes that may predict incomplete recovery of LV function. For any patient whose LVEF fails to normalize with correction of the tachyarrhythmia, other underlying pathology should be considered including permanent structural changes [<a href="#rid90">90,109</a>]. If arrhythmia-induced cardiomyopathy recurs, these patients are at substantial risk for sudden death, and ICD implantation should be contemplated [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H765649630"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">"Society guideline links: Ventricular arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">"Society guideline links: Cardiac implantable electronic devices"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H20079204"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3431.html" rel="external">"Patient education: Atrial fibrillation (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3449.html" rel="external">"Patient education: Catheter ablation for abnormal heartbeats (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Arrhythmia-induced cardiomyopathy is a relatively rare cause of a dilated cardiomyopathy resulting from prolonged periods of rapid ventricular heart rates. Arrhythmia-induced cardiomyopathy often improves or resolves following treatment and is associated with a good prognosis in most patients. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Chronic tachycardia ultimately produces significant structural changes in the heart, with impressive left ventricular (LV) dilation and cellular morphologic changes leading to a cardiomyopathy. The precise mechanism(s) by which a chronic tachycardia produces these changes remain incompletely described. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Association with specific arrhythmias</strong> – Virtually all tachyarrhythmias have been reported to cause arrhythmia-induced cardiomyopathy, and frequent ectopic beats have also been associated with this condition. In most cases, the myocardial dysfunction improves or normalizes following therapy to control the ventricular heart rate or to restore normal sinus rhythm. (See <a class="local">'Arrhythmias associated with arrhythmia-induced cardiomyopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The clinical presentation of arrhythmia-induced cardiomyopathy is variable but usually involves signs and/or symptoms related to the tachyarrhythmia (eg, palpitations, dyspnea, chest discomfort, etc), heart failure (HF; eg, dyspnea, edema, weight gain, orthopnea, etc), or both. In our experience, HF symptoms are more common since patients with symptomatic tachyarrhythmias will frequently seek medical attention earlier in the course of their care and prior to the development of a cardiomyopathy. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ECG findings</strong> – All patients should have an ECG to document the cardiac rhythm and ventricular heart rate, with comparison to prior ECGs when available. There are no specific ECG findings that distinguish patients with and without arrhythmia-induced cardiomyopathy, and the ECG findings will vary depending upon the underlying tachyarrhythmia. (See <a class="local">'ECG findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to diagnosis</strong> – Arrhythmia-induced cardiomyopathy is defined by the presence of a sustained tachycardia (or frequent episodes of tachycardia or very frequent ectopy) that results in with LV systolic dysfunction. Usually the diagnosis of arrhythmia-induced cardiomyopathy can only be made following a successful trial of therapy to slow the ventricular rate or to restore sinus rhythm along with the exclusion of other potential causes of cardiomyopathy. Patients in whom arrhythmia-induced cardiomyopathy is suspected should undergo continuous cardiac monitoring for 24 to 48 hours and have non-invasive imaging to assess cardiac structure and function. For most patients, a transthoracic echocardiogram is the preferred test for assessing cardiac structure and function, although cardiovascular magnetic resonance (CMR) imaging is a reasonable alternative. (See <a class="local">'Approach to the diagnosis'</a> above and <a class="local">'Diagnostic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> –<strong> </strong>The initial treatments for a patient with HF and suspected arrhythmia-induced cardiomyopathy are the same as those used in most other patients with HF (eg, angiotensin converting enzyme [ACE] inhibitors or angiotensin II receptor blockers [ARBs], beta blockers, diuretics) and tachyarrhythmias (eg, rate-control medications, consideration of antiarrhythmic drugs and/or cardioversion). However, because of the potential reversible nature of arrhythmia-induced cardiomyopathy, aggressive efforts should be made to achieve excellent ventricular heart rate control or to restore sinus rhythm. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For minimally symptomatic patients with atrial fibrillation (AF) in whom adequate rate control is achieved, we continue medical therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with AF who remain significantly symptomatic, or patients in whom adequate rate control is not achieved with medical therapy alone, we pursue a rhythm control strategy. (See  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a> and  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with atrial flutter, rapid ventricular rates, and newly recognized depressed LV ejection fraction (LVEF), rate control may be difficult to achieve with medication. Because of this, we perform early electrical cardioversion in these patients. (See  <a class="medical medical_review" href="/z/d/html/1069.html" rel="external">"Restoration of sinus rhythm in atrial flutter"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For supraventricular tachyarrhythmias (SVTs) other than AF or atrial flutter that result in arrhythmia-induced cardiomyopathy, restoration of sinus rhythm is the usual goal. The initial choice of modality (ie, electrical cardioversion, antiarrhythmic drugs, or catheter ablation of the arrhythmia) will vary depending upon the underlying SVT as well as the local expertise and availability of options.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients presenting with a high burden of premature ventricular complexes/contractions (PVCs) and associated with LV dysfunction, we generally pursue radiofrequency catheter ablation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On rare occasions when all efforts at ventricular rate control, restoration of sinus rhythm, and catheter ablation of the arrhythmia have been unsuccessful for the treatment of SVTs, ablation of the AV node with insertion of a permanent pacemaker may be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term monitoring</strong> – Close ongoing monitoring with clinic visits, ambulatory (Holter) monitoring, and echocardiography is essential to assess for any recurrence. We follow up with patients using a combination of clinic visits, echocardiography, and ambulatory monitoring every three to six months for one to two years following the initial clinical improvement. (See <a class="local">'Follow-up'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Westphal JG, Rigopoulos AG, Bakogiannis C, et al. The MOGE(S) classification for cardiomyopathies: current status and future outlook. Heart Fail Rev 2017; 22:743.</a></li><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 2017; 23:628.</a></li><li><a class="nounderline abstract_t">Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29:709.</a></li><li><a class="nounderline abstract_t">Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol 2015; 66:1714.</a></li><li><a class="nounderline abstract_t">Kasper EK, Agema WR, Hutchins GM, et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994; 23:586.</a></li><li><a class="nounderline abstract_t">SHACHNOW N, SPELLMAN S, RUBIN I. Persistent supraventricular tachycardia; case report with review of literature. Circulation 1954; 10:232.</a></li><li><a class="nounderline abstract_t">Engel TR, Bush CA, Schaal SF. Tachycardia-aggravated heart disease. Ann Intern Med 1974; 80:384.</a></li><li><a class="nounderline abstract_t">Coleman HN 3rd, Taylor RR, Pool PE, et al. Congestive heart failure following chronic tachycardia. Am Heart J 1971; 81:790.</a></li><li><a class="nounderline abstract_t">Vijgen J, Hill P, Biblo LA, Carlson MD. Tachycardia-induced cardiomyopathy secondary to right ventricular outflow tract ventricular tachycardia: improvement of left ventricular systolic function after radiofrequency catheter ablation of the arrhythmia. J Cardiovasc Electrophysiol 1997; 8:445.</a></li><li><a class="nounderline abstract_t">Singh B, Kaul U, Talwar KK, Wasir HS. Reversibility of "tachycardia induced cardiomyopathy" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol 1996; 19:1391.</a></li><li><a class="nounderline abstract_t">Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010; 7:865.</a></li><li><a class="nounderline abstract_t">Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol 2009; 53:1791.</a></li><li><a class="nounderline abstract_t">Donghua Z, Jian P, Zhongbo X, et al. Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia. J Interv Card Electrophysiol 2013; 36:27.</a></li><li><a class="nounderline abstract_t">Brembilla-Perrot B, Ferreira JP, Manenti V, et al. Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation. Eur J Heart Fail 2016; 18:394.</a></li><li><a class="nounderline abstract_t">Spinale FG, Hendrick DA, Crawford FA, et al. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol 1990; 259:H218.</a></li><li><a class="nounderline abstract_t">Howard RJ, Stopps TP, Moe GW, et al. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol 1988; 66:1505.</a></li><li><a class="nounderline abstract_t">Morgan DE, Tomlinson CW, Qayumi AK, et al. Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing. J Am Coll Cardiol 1989; 14:489.</a></li><li><a class="nounderline abstract_t">Spinale FG, Tomita M, Zellner JL, et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991; 261:H308.</a></li><li><a class="nounderline abstract_t">Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995; 92:2306.</a></li><li><a class="nounderline abstract_t">O'Brien PJ, Ianuzzo CD, Moe GW, et al. Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies. Can J Physiol Pharmacol 1990; 68:34.</a></li><li><a class="nounderline abstract_t">Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation 1994; 89:2241.</a></li><li><a class="nounderline abstract_t">Armstrong PW, Stopps TP, Ford SE, de Bold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 1986; 74:1075.</a></li><li><a class="nounderline abstract_t">Wilson JR, Douglas P, Hickey WF, et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987; 75:857.</a></li><li><a class="nounderline abstract_t">Damiano RJ Jr, Tripp HF Jr, Asano T, et al. Left ventricular dysfunction and dilatation resulting from chronic supraventricular tachycardia. J Thorac Cardiovasc Surg 1987; 94:135.</a></li><li><a class="nounderline abstract_t">Yamamoto K, Burnett JC Jr, Meyer LM, et al. Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model. Am J Physiol 1996; 271:R1529.</a></li><li><a class="nounderline abstract_t">Huizar JF, Kaszala K, Potfay J, et al. Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy. Circ Arrhythm Electrophysiol 2011; 4:543.</a></li><li><a class="nounderline abstract_t">Pak PH, Nuss HB, Tunin RS, et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol 1997; 30:576.</a></li><li><a class="nounderline abstract_t">Moe GW, Montgomery C, Howard RJ, et al. Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med 1993; 121:294.</a></li><li><a class="nounderline abstract_t">Spinale FG, Holzgrefe HH, Mukherjee R, et al. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol 1995; 268:H836.</a></li><li><a class="nounderline abstract_t">Spinale FG, Clayton C, Tanaka R, et al. Myocardial Na+,K(+)-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 1992; 24:277.</a></li><li><a class="nounderline abstract_t">Kloner RA, DeBoer LW, Darsee JR, et al. Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci U S A 1981; 78:7152.</a></li><li><a class="nounderline abstract_t">Reimer KA, Hill ML, Jennings RB. Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J Mol Cell Cardiol 1981; 13:229.</a></li><li><a class="nounderline abstract_t">Spinale FG, Tanaka R, Crawford FA, Zile MR. Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation 1992; 85:717.</a></li><li><a class="nounderline abstract_t">Shannon RP, Komamura K, Shen YT, et al. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol 1993; 265:H801.</a></li><li><a class="nounderline abstract_t">Perreault CL, Shannon RP, Komamura K, et al. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest 1992; 89:932.</a></li><li><a class="nounderline abstract_t">Tanaka R, Fulbright BM, Mukherjee R, et al. The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol 1993; 25:1215.</a></li><li><a class="nounderline abstract_t">Sasayama S, Asanoi H, Ishizaka S. Continuous measurement of the pressure-volume relationship in experimental heart failure produced by rapid ventricular pacing in conscious dogs. Eur Heart J 1992; 13 Suppl E:47.</a></li><li><a class="nounderline abstract_t">Selby DE, Palmer BM, LeWinter MM, Meyer M. Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol 2011; 58:147.</a></li><li><a class="nounderline abstract_t">Marzo KP, Frey MJ, Wilson JR, et al. Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing. Circ Res 1991; 69:1546.</a></li><li><a class="nounderline abstract_t">Wakili R, Yeh YH, Yan Qi X, et al. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol 2010; 3:530.</a></li><li><a class="nounderline abstract_t">Yonemochi H, Yasunaga S, Teshima Y, et al. Rapid electrical stimulation of contraction reduces the density of beta-adrenergic receptors and responsiveness of cultured neonatal rat cardiomyocytes. Possible involvement of microtubule disassembly secondary to mechanical stress. Circulation 2000; 101:2625.</a></li><li><a class="nounderline abstract_t">Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104:174.</a></li><li><a class="nounderline abstract_t">Shite J, Qin F, Mao W, et al. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J Am Coll Cardiol 2001; 38:1734.</a></li><li><a class="nounderline abstract_t">Deshmukh PM, Krishnamani R, Romanyshyn M, et al. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 2004; 13:455.</a></li><li><a class="nounderline abstract_t">Mueller KAL, Heinzmann D, Klingel K, et al. Reply: Histopathological and Immunological Characteristics of Tachycardia-Induced Cardiomyopathy. J Am Coll Cardiol 2017; 70:1687.</a></li><li><a class="nounderline abstract_t">Chiladakis JA, Vassilikos VP, Maounis TN, et al. Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture. Pacing Clin Electrophysiol 1997; 20:953.</a></li><li><a class="nounderline abstract_t">Gillette PC, Smith RT, Garson A Jr, et al. Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy. JAMA 1985; 253:391.</a></li><li><a class="nounderline abstract_t">Gallagher JJ. Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited. J Am Coll Cardiol 1985; 6:1172.</a></li><li><a class="nounderline abstract_t">Bertil Olsson S, Blomström P, Sabel KG, William-Olsson G. Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture. Am J Cardiol 1984; 53:1465.</a></li><li><a class="nounderline abstract_t">Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563.</a></li><li><a class="nounderline abstract_t">Rao PS, Najjar HN. Congestive cardiomyopathy due to chronic tachycardia: resolution of cardiomyopathy with antiarrhythmic drugs. Int J Cardiol 1987; 17:216.</a></li><li><a class="nounderline abstract_t">Gillette PC, Wampler DG, Garson A Jr, et al. Treatment of atrial automatic tachycardia by ablation procedures. J Am Coll Cardiol 1985; 6:405.</a></li><li><a class="nounderline abstract_t">Sanders P, Morton JB, Kistler PM, et al. Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy. Circulation 2003; 108:1976.</a></li><li><a class="nounderline abstract_t">Fishberger SB, Colan SD, Saul JP, et al. Myocardial mechanics before and after ablation of chronic tachycardia. Pacing Clin Electrophysiol 1996; 19:42.</a></li><li><a class="nounderline abstract_t">Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. Pacing Clin Electrophysiol 1998; 21:2073.</a></li><li><a class="nounderline abstract_t">Leman RB, Gillette PC, Zinner AJ. Resolution of congestive cardiomyopathy caused by supraventricular tachycardia using amiodarone. Am Heart J 1986; 112:622.</a></li><li><a class="nounderline abstract_t">Corey WA, Markel ML, Hoit BD, Walsh RA. Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia. Am Heart J 1993; 126:1469.</a></li><li><a class="nounderline abstract_t">Grimm W, Menz V, Hoffmann J, Maisch B. Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol 2001; 24:166.</a></li><li><a class="nounderline abstract_t">Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005; 112:1092.</a></li><li><a class="nounderline abstract_t">Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004; 110:247.</a></li><li><a class="nounderline abstract_t">Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113:359.</a></li><li><a class="nounderline abstract_t">Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998; 32:205.</a></li><li><a class="nounderline abstract_t">Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000; 75:790.</a></li><li><a class="nounderline abstract_t">Edner M, Caidahl K, Bergfeldt L, et al. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J 1995; 74:261.</a></li><li><a class="nounderline abstract_t">Pizzale S, Lemery R, Green MS, et al. Frequency and predictors of tachycardia-induced cardiomyopathy in patients with persistent atrial flutter. Can J Cardiol 2009; 25:469.</a></li><li><a class="nounderline abstract_t">Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol 2011; 22:663.</a></li><li><a class="nounderline abstract_t">Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007; 4:863.</a></li><li><a class="nounderline abstract_t">Yokokawa M, Kim HM, Good E, et al. Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm 2012; 9:92.</a></li><li><a class="nounderline abstract_t">Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm 2011; 8:1608.</a></li><li><a class="nounderline abstract_t">Penela D, Van Huls Van Taxis C, Aguinaga L, et al. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol 2013; 62:1195.</a></li><li><a class="nounderline abstract_t">El Kadri M, Yokokawa M, Labounty T, et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. Heart Rhythm 2015; 12:706.</a></li><li><a class="nounderline abstract_t">Baser K, Bas HD, LaBounty T, et al. Recurrence of PVCs in patients with PVC-induced cardiomyopathy. Heart Rhythm 2015; 12:1519.</a></li><li><a class="nounderline abstract_t">Penela D, Acosta J, Aguinaga L, et al. Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant. Heart Rhythm 2015; 12:2434.</a></li><li><a class="nounderline abstract_t">Laplante L, Benzaquen BS. A Review of the Potential Pathogenicity and Management of Frequent Premature Ventricular Contractions. Pacing Clin Electrophysiol 2016; 39:723.</a></li><li><a class="nounderline abstract_t">Lamba J, Redfearn DP, Michael KA, et al. Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis. Pacing Clin Electrophysiol 2014; 37:73.</a></li><li><a class="nounderline abstract_t">Yokokawa M, Kim HM, Good E, et al. Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy. Heart Rhythm 2012; 9:1460.</a></li><li><a class="nounderline abstract_t">Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular premature depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced cardiomyopathy. Heart Rhythm 2014; 11:299.</a></li><li><a class="nounderline abstract_t">Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9:1465.</a></li><li><a class="nounderline abstract_t">Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm 2013; 10:172.</a></li><li><a class="nounderline abstract_t">Walters TE, Rahmutula D, Szilagyi J, et al. Left Ventricular Dyssynchrony Predicts the Cardiomyopathy Associated With Premature Ventricular Contractions. J Am Coll Cardiol 2018; 72:2870.</a></li><li><a class="nounderline abstract_t">Pacchia CF, Akoum NW, Wasmund S, Hamdan MH. Atrial bigeminy results in decreased left ventricular function: an insight into the mechanism of PVC-induced cardiomyopathy. Pacing Clin Electrophysiol 2012; 35:1232.</a></li><li><a class="nounderline abstract_t">Hasdemir C, Simsek E, Yuksel A. Premature atrial contraction-induced cardiomyopathy. Europace 2013; 15:1790.</a></li><li><a class="nounderline abstract_t">Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.</a></li><li><a class="nounderline abstract_t">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599.</a></li><li><a class="nounderline abstract_t">Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.</a></li><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136:e137.</a></li><li><a class="nounderline abstract_t">Sakaguchi H, Miyazaki A, Yamamoto M, et al. Clinical characteristics of focal atrial tachycardias arising from the atrial appendages during childhood. Pacing Clin Electrophysiol 2011; 34:177.</a></li><li><a class="nounderline abstract_t">Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.</a></li><li><a class="nounderline abstract_t">Jeong YH, Choi KJ, Song JM, et al. Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 2008; 31:172.</a></li><li><a class="nounderline abstract_t">Ling LH, Kalman JM, Ellims AH, et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol 2013; 6:697.</a></li><li><a class="nounderline abstract_t">Hasdemir C, Yuksel A, Camli D, et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol 2012; 35:465.</a></li><li><a class="nounderline abstract_t">Kusunose K, Torii Y, Yamada H, et al. Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF. JACC Cardiovasc Imaging 2017; 10:118.</a></li><li><a class="nounderline abstract_t">Ortiz-Genga M, García-Hernández S, Monserrat-Iglesias L, McKenna WJ. Preventing Sudden Death in Arrhythmogenic Cardiomyopathy: Careful Family and Genetic Evaluation Key to Appropriate Diagnosis and Management. Can J Cardiol 2021; 37:819.</a></li><li><a class="nounderline abstract_t">Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol 2016; 68:2440.</a></li><li><a class="nounderline abstract_t">Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570.</a></li><li><a class="nounderline abstract_t">Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18:9.</a></li><li><a class="nounderline abstract_t">Manolis AG, Katsivas AG, Lazaris EE, et al. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol 1998; 2:71.</a></li><li><a class="nounderline abstract_t">Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol 2017; 70:1949.</a></li><li><a class="nounderline abstract_t">Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009; 119:2516.</a></li><li><a class="nounderline abstract_t">Latchamsetty R, Bogun F. Premature Ventricular Complex-Induced Cardiomyopathy. JACC Clin Electrophysiol 2019; 5:537.</a></li><li><a class="nounderline abstract_t">Eugenio PL. Frequent Premature Ventricular Contractions: An Electrical Link to Cardiomyopathy. Cardiol Rev 2015; 23:168.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.</a></li><li><a class="nounderline abstract_t">Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005; 45:1259.</a></li><li><a class="nounderline abstract_t">Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm 2014; 11:187.</a></li><li><a class="nounderline abstract_t">Berruezo A, Penela D, Jáuregui B, et al. Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction. Europace 2019; 21:1079.</a></li><li><a class="nounderline abstract_t">Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018; 39:3999.</a></li><li><a class="nounderline abstract_t">Dandamudi G, Rampurwala AY, Mahenthiran J, et al. Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction. Heart Rhythm 2008; 5:1111.</a></li><li><a class="nounderline abstract_t">Moe GW, Armstrong P. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res 1999; 42:591.</a></li><li><a class="nounderline abstract_t">Ling LH, Taylor AJ, Ellims AH, et al. Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. Heart Rhythm 2013; 10:1334.</a></li></ol></div><div id="topicVersionRevision">Topic 1062 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28721466" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The MOGE(S) classification for cardiomyopathies: current status and future outlook.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461259" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9091514" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26449143" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113538" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13182756" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Persistent supraventricular tachycardia; case report with review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4816181" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tachycardia-aggravated heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5088355" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Congestive heart failure following chronic tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9106431" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tachycardia-induced cardiomyopathy secondary to right ventricular outflow tract ventricular tachycardia: improvement of left ventricular systolic function after radiofrequency catheter ablation of the arrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8880807" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reversibility of "tachycardia induced cardiomyopathy" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348027" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relationship between burden of premature ventricular complexes and left ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422986" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090777" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26833591" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375409" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3228785" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recovery from heart failure: structural and functional analysis in a canine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2754134" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1877659" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7554216" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2328442" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181149" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2945673" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3829344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3599999" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Left ventricular dysfunction and dilatation resulting from chronic supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8997349" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576277" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247535" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433042" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864211" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320703" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Myocardial Na+,K(+)-ATPase in tachycardia induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7031671" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7265245" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735164" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214113" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311723" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8263955" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1478209" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Continuous measurement of the pressure-volume relationship in experimental heart failure produced by rapid ventricular pacing in conscious dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21718911" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1659503" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660541" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10840015" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Rapid electrical stimulation of contraction reduces the density of beta-adrenergic receptors and responsiveness of cultured neonatal rat cardiomyocytes. Possible involvement of microtubule disassembly secondary to mechanical stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11447082" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704389" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767579" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28935050" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reply: Histopathological and Immunological Characteristics of Tachycardia-Induced Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9127401" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965793" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3876364" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6720596" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3953440" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3679604" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Congestive cardiomyopathy due to chronic tachycardia: resolution of cardiomyopathy with antiarrhythmic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4019927" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of atrial automatic tachycardia by ablation procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557372" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8848376" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Myocardial mechanics before and after ablation of chronic tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9826859" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3751876" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Resolution of congestive cardiomyopathy caused by supraventricular tachycardia using amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8249807" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11270695" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103234" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15226218" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401529" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669271" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Resolution of cardiomyopathy after ablation of atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10943231" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7547020" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19668781" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Frequency and predictors of tachycardia-induced cardiomyopathy in patients with persistent atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21235667" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599667" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855522" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699837" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23850913" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527251" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25791642" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Recurrence of PVCs in patients with PVC-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26385530" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27073007" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A Review of the Potential Pathogenicity and Management of Frequent Premature Ventricular Contractions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980900" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22542704" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24184787" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Ventricular premature depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640894" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23099051" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30522650" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Left Ventricular Dyssynchrony Predicts the Cardiomyopathy Associated With Premature Ventricular Contractions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22845488" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Atrial bigeminy results in decreased left ventricular function: an insight into the mechanism of PVC-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759338" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Premature atrial contraction-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16450016" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34447992" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610207" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : HFSA 2010 Comprehensive Heart Failure Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28455343" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883515" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinical characteristics of focal atrial tachycardias arising from the atrial appendages during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504425" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18404727" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23884195" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22303908" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27665160" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33359000" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Preventing Sudden Death in Arrhythmogenic Cardiomyopathy: Careful Family and Genetic Evaluation Key to Appropriate Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27908349" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1598871" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17081210" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Reversal of left ventricular dysfunction following ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869999" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28855115" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433768" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Atrial fibrillation and heart failure: treatment considerations for a dual epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122375" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Premature Ventricular Complex-Induced Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741605" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Frequent Premature Ventricular Contractions: An Electrical Link to Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837259" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24157533" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30904923" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165479" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18675220" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10533598" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23811081" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
